Bristol-Myers Squibb (BMY)

$39.66 0.20 (0.51%)

19:00 EDT BMY Stock Quote Delayed 30 Minutes

Millionaire’s Blueprint: 7 Must-Have Stocks for Your Road to Wealthy Town

By Yiannis Zourmpanos, InvestorPlace Contributor Mar 6, 2024

Discover must-have stocks for wealth for every investor, from healthcare and communication giants to financial and industrial sectors.

Mental Health Mavericks: 3 Stocks Changing the Game

The 3 Best Stocks Beginning Investors Can Buy: February 2024

7 Contrarian Biotech Stocks to Consider Amid Sector Weakness

Volume:

Previous Close -

Market Cap 88.13B

PE Ratio -12.79

EPS -3.1

Volume (Avg. Vol.) 12.82M

Day's Range $39.35 - $39.75

52-Week Range $39.35 - $65.38

Dividend & Yield $2.28 (5.75%)

BMY Stock Predictions, Articles, and Bristol-Myers Squibb News

7 Dividend Stocks to Buy at a 52-Week Low

By Chris Markoch, InvestorPlace Contributor Feb 12, 2024

Each of these dividend stocks has been down sharply in the last 12 months but has fundamental reasons that support a turnaround.

7 Biotech Stocks Fighting America’s Deadliest Diseases

By Josh Enomoto, InvestorPlace Contributor Feb 8, 2024

Unlike many other market segments, biotech stocks stand out for their direct relevance. For example, investors who typically wager on aerospace and defense plays usually…

3 Blue-Chip Stocks to Buy at a 52-Week Low in February

By Chris Markoch, InvestorPlace Contributor Feb 7, 2024

Higher-for-longer interest rates and undervalued metrics make it a good time to look for blue-chip stocks at a low price.

Undervalued Gems: 7 Stocks Set for a Major Rebound

By Thomas Niel, InvestorPlace Contributor Feb 5, 2024

Each of these seven undervalued stocks has fallen by 25% or more from its 52-week high, but may have a path back to prior prices.

3 Healthcare Stocks at 52-Week Lows: Buy or Bye?

By Alex Sirois, InvestorPlace Contributor Jan 26, 2024

Investors should consider picking up these healthcare stocks at 52-week lows to benefit from their potential rebound.

7 Beaten-Down Value Stocks Poised for an Epic Turnaround

By Omor Ibne Ehsan Jan 23, 2024

Battered value stocks could be priced for an epic rebound in 2024 and beyond. These seven can quickly escape Wall Street's penalty box.

3 Dividend Stocks for Strong Returns in 2024 and Beyond

By Bob Ciura, Sure Dividend Jan 4, 2024

Investors should consider these three dividend stocks for 2024 and beyond, as they offer compelling yields and safety.

7 Stocks Primed for a Spectacular Comeback in 2024

By Josh Enomoto, InvestorPlace Contributor Jan 3, 2024

While investors might be tempted to ride the biggest winners of last year, shifting sands may provide a superior outlook for comeback stocks. Just what…

Why Is RayzeBio (RYZB) Stock Up 100% Today?

By Dana Blankenhorn, InvestorPlace Contributor Dec 26, 2023

RYZB stock has doubled today after Bristol Myers Squibb shelled out $4.1 billion to buy RayzeBio. Expect more such deals in 2024.

3 Potential Turnaround Stocks to Buy for Big Rewards in 2024

By Ian Cooper, InvestorPlace Contributor Dec 20, 2023

There was plenty to get excited about in 2023 and even more to get excited about with turnaround stocks in the new year.

7 Stocks with Strong Insider Buying: December 2023

By Chris Markoch, InvestorPlace Contributor Dec 17, 2023

Stocks with strong insider buying should make you curious, and finding them can be a useful shortcut for your research

Why Is Avidity Biosciences (RNA) Stock Up 15% Today?

By Larry Ramer, InvestorPlace Contributor Nov 28, 2023

RNA stock is jumping over 15% in early trading after Avidity announced its expanded alliance with Bristol-Myers Squibb.

3 Resilient Stocks with Massive Potential to Boost Your Wealth

By Rich Duprey, InvestorPlace Contributor Nov 26, 2023

These three stocks with massive potential can make patient investors fabuslously wealthy as they come roaring back to life.

Soothing Stocks: 7 Reliable Picks to Ease Your Market Jitters

By Josh Enomoto, InvestorPlace Contributor Nov 20, 2023

Based on the strong print of the major indices since late last month, the idea of deliberately targeting reliable stocks for a volatile market might…

Why Is Bristol-Myers Squibb (BMY) Stock Down Today?

By William White, InvestorPlace Writer Nov 20, 2023

Bristol-Myers Squibb stock is falling on Monday as investors in BMY shares react to two updates weighing on the company's stock.

Debt-Fueled Buybacks: 3 Stocks Undeterred by Rising Rates

By Will Ashworth, InvestorPlace Contributor Nov 13, 2023

Share repurchases have slowed in 2023, partly due to the 1% tax. Here are three buybacks partially paid for with debt offerings.

Why Is LianBio (LIAN) Stock Up 130% Today?

By Josh Enomoto, InvestorPlace Contributor Oct 24, 2023

With LianBio inking a key exclusive licensing agreement with Bristol-Myers Squibb, LIAN stock is jumping up on the credibility implications.

7 Healthcare Stocks That Can Cure a Lackluster Portfolio

By Joel Baglole, InvestorPlace Contributor Oct 19, 2023

Take a position in these companies' stocks to achieve long-term gains and give a jolt to your investment portfolio.

7 Innovator Stocks Primed for Exceptional Growth

By Chandler Capital, InvestorPlace Contributor Oct 10, 2023

As the market continues to rebound, investors should keep an eye on these companies at the forefront of innovation. They stand poised to surge ahead of their competition in terms of revenue and earnings.

Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs

By Larry Ramer, InvestorPlace Contributor Oct 2, 2023

CAR T therapies have major advantages over traditional cancer drugs. Here are three of the best cancer drug stocks set to benefit from CAR T.

Bristol-Myers Squibb (BMY)

Millionaire’s Blueprint: 7 Must-Have Stocks for Your Road to Wealthy Town

Mental Health Mavericks: 3 Stocks Changing the Game

The 3 Best Stocks Beginning Investors Can Buy: February 2024

7 Contrarian Biotech Stocks to Consider Amid Sector Weakness

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Bristol-Myers Squibb (BMY)

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

BMY Stock Predictions, Articles, and Bristol-Myers Squibb News

Subscriber Sign in